Omscientia to Offer the Zenobia Therapeutics Fragment Library for Fragment Screening

Omscientia is excited to be offering the unique Fragment Screen, which was developed by the Zenobia Therapeutics research team lead by CEO, Vicki Nienaber, pioneer of the Fragment Screening Method.

Fragment-based lead discovery, first reported in the mid-1990, is a powerful drug discovery tool yielding more than 10 clinical candidates.  Overall, these candidates have chemical properties more consistent with marketed drugs than candidates discovered by other methods in part because the starting points are low molecular weight.  Fragment hits usually bind very efficiently and have been optimized to IND candidates in less than 2 years.

When developed by Zenobia, the criteria for this library were far more stringent than the commonly quoted “rule-of-three.”  Potencies for compounds with these properties typically range from 1-10,000 uM.  Highly soluble (200mM in 100% DMSO), the library is suitable for screening with NMR, SPR and x-ray crystallography.  There are 352 compounds in total which ship as dry films in 96 well plates.  Compounds are pre-grouped into shape-diverse mixtures for crystallographic screens.
 
Omscientia and Zenobia Therapeutics are both excited about the new agreement and believe it will help make Fragment Screening more widely available to labs worldwide while also reducing the investment required to do fragment screening.  The Fragment Library is available immediately as a kit that can be purchased by labs wishing to employ Fragment-Based Lead Discovery.